Cargando…

2487. Low Rate of Virologic Failure in Antiretroviral Experienced Patients Prescribed Once Daily Raltegravir

BACKGROUND: Raltegravir has been used to treat HIV infection for over a decade. In 2017, a 1200 mg, once-daily, formulation of raltegravir (RALQD) was approved. We sought to characterize the utilization and effectiveness of RALQD in ART-experienced, virologically suppressed, HIV+ adults in a real-wo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Ricky, Schulman, Kathy, Fusco, Jennifer S, Marie Arduino, Jean, Prajapati, Girish, Fusco, Gregory
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810617/ http://dx.doi.org/10.1093/ofid/ofz360.2165

Ejemplares similares

555. Characteristics of HIV+ Patients Prescribed Raltegravir QD in the United States
por: Lackey, Philip, et al.
Publicado: (2018)

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
por: Gutierrez-Valencia, Alicia, et al.
Publicado: (2015)

978. Changes in BMI Associated with Antiretroviral Regimens in Treatment-Experienced, Virologically Suppressed Individuals Living with HIV
por: Mounzer, Karam, et al.
Publicado: (2019)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
por: Hall, Nolwenn, et al.
Publicado: (2022)

Two‐drug antiretroviral regimens: an assessment of virologic response and durability among treatment‐experienced persons living with HIV in the OPERA(®) Observational Database
por: Pierone, Gerald, et al.
Publicado: (2019)

Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
por: Lackey, Philip, et al.
Publicado: (2016)

Use of once-daily raltegravir-based HAART in HIV-infected injection drug users
por: Tossonian, HK, et al.
Publicado: (2010)

Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients
por: Mata-Marín, José Antonio, et al.
Publicado: (2017)

2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen
por: Wohlfeiler, Michael, et al.
Publicado: (2019)

1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort
por: Sension, Michael, et al.
Publicado: (2023)

557. Evaluation of Clinical Response of a Two Tablet Once Daily Antiretroviral Regimen in Antiretroviral Experienced HIV-Infected Patients
por: Maki, Gina, et al.
Publicado: (2018)

A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200 mg in pregnant women living with HIV
por: Bukkems, Vera E., et al.
Publicado: (2021)

PB2487: SECONDARY HLH: RETROSPECTIVE DATA FROM TERTIARY CARE CENTRE.
por: Wasekar, Nilesh, et al.
Publicado: (2023)

The biosynthetic pathway to tetromadurin (SF2487/A80577), a polyether tetronate antibiotic
por: Little, Rory F., et al.
Publicado: (2020)

Virologic Outcomes Among People Living With Human Immunodeficiency Virus With High Pretherapy Viral Load Burden Initiating on Common Core Agents
por: Mills, Anthony M, et al.
Publicado: (2021)

Antiretroviral therapy and liver disorders in the OPERA(®) cohort
por: Wohlfeiler, Michael, et al.
Publicado: (2020)

Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes
por: Hsu, Ricky K., et al.
Publicado: (2023)

Clinical, immunological, and virological outcomes in HIV patients on raltegravir-based salvage therapy
por: Deshwal, Rajesh, et al.
Publicado: (2019)

HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens
por: Kapadia, Shashi N, et al.
Publicado: (2018)

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
por: Chirch, Lisa M, et al.
Publicado: (2010)

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
por: Castagna, Antonella, et al.
Publicado: (2014)

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
por: Cozzi‐Lepri, A, et al.
Publicado: (2017)

Weight gain before and after switch from TDF to TAF in a U.S. cohort study
por: Mallon, Patrick WG, et al.
Publicado: (2021)

936. Body Fat Redistribution/Accumulation, Pancreatic Disorders, Musculoskeletal Disorders, IRIS, Severe Systemic Rash and Hypersensitivity Reactions Following Initiation of Commonly Prescribed Antiretrovirals
por: Lackey, Philip, et al.
Publicado: (2018)

Cryptococcal Antigenemia in Human Immunodeficiency Virus Antiretroviral Therapy–Experienced Ugandans With Virologic Failure
por: Mpoza, Edward, et al.
Publicado: (2019)

2487. Which Extended-Spectrum β-Lactamase-Producing Enterobacterales Colonize the Gastrointestinal Tract of High-Risk Patients?
por: Stambaugh, Haley, et al.
Publicado: (2023)

Combination Therapy with Tenofovir Disoproxil Fumarate/Emtricitabine/Elvitegravir/Cobicistat Plus Darunavir Once Daily in Antiretroviral-Naive and Treatment-Experienced Patients: A Retrospective Review
por: Naccarato, Mark J., et al.
Publicado: (2018)

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
por: Geretti, Anna Maria, et al.
Publicado: (2015)

Long-term outcomes of highly experienced people with HIV undergoing salvage therapy with raltegravir
por: Patiño Escarcina, Jesús Enrique, et al.
Publicado: (2023)

341. Risk of Type 2 Diabetes Mellitus after Antiretroviral Therapy Initiation in Individuals Living with HIV in the United States
por: Hsu, Ricky, et al.
Publicado: (2019)

Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir
por: Ouyang, Zhengyu, et al.
Publicado: (2015)

2487. Vaccination Rates in Post-Transplant Hematopoietic Stem Cell Transplant (HSCT) Patients: Where Do We Stand?
por: Ahmad, Hiba, et al.
Publicado: (2018)

Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen
por: Engsig, Frederik N, et al.
Publicado: (2010)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
por: Ferrer, Pablo, et al.
Publicado: (2020)

Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting
por: Chehadeh, Wassim, et al.
Publicado: (2020)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Impact of Tablet Burden and Antiretroviral Therapy (ART) Choice on Virologic Outcomes in Treatment Naive HIV+ Individuals Attending an Inner City Clinic
por: Markowitz, Norman, et al.
Publicado: (2017)

Validation of the Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) chronic kidney disease risk score in HIV‐infected patients in the USA
por: Mills, AM, et al.
Publicado: (2020)

Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?
por: Nachega, Jean B, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_s8o9fn2vhbsgmm96hqt3a9er0e